CBD has small affinity for CB receptors. It functions being an antagonist or partial antagonist at endogenous cannabinoid receptors (both equally CB1 and CB2 receptor kinds together with other G-protein-coupled receptors [GPCRs]) by inhibiting full binding of direct ligands, and will act primari